News Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
- Jun 05, 2019
BRISBANE, Calif.--(BUSINESS WIRE)--Jun. 5, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced...
- Jun 04, 2019— VERU-100 Is a Proprietary Peptide Formulation Designed with Multiple Beneficial Clinical Attributes Addressing the Shortfalls of the Current Multi-Billion-Dollar Androgen Deprivation Therapy Market — — Reached Agreement with FDA on an Expedited Regulatory Pathway and Clinical Development Strategy —
MIAMI, June 04, 2019 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and prostate cancer...
- Jun 04, 2019--APPEAL 2: Struggle to Avoid Accidental Peanut Exposure Negatively Impacts Quality of Life for Patients and Families--
LISBON, Portugal--(BUSINESS WIRE)--Jun. 4, 2019-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced...
- Jun 03, 2019
FARMINGDALE, N.Y., June 03, 2019 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that...
- Jun 02, 2019
LISBON, Portugal--(BUSINESS WIRE)--Jun. 2, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today presented...
- May 30, 2019
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (“Acerus” or “the Company”) (TSX:ASP; OTCQB:ASPCF) announced today that it has signed a patent license agreement (the...
- May 29, 2019
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced that President and CEO Todd Norbe and Executive Vice President and CFO John Beaver are scheduled to present at the 9th
- May 28, 2019
MIAMI, May 28, 2019 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and prostate cancer...
- May 28, 2019Enteris BioPharma to Present at New Rhein Healthcare Inaugural Industry Day 2019
Boonton, NJ – May 28, 2019 – Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary oral peptide delivery technologies, announced...
- May 24, 2019– Full Results from Phase 3 ARTEMIS Study Will Be Featured –
BRISBANE, Calif.--(BUSINESS WIRE)--May 24, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced...
- May 21, 2019-- 4 in 10 Teens believe they have a great or very great chance or certainty of dying from accidental exposure --
NEW ORLEANS--(BUSINESS WIRE)--May 21, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced...
- May 20, 2019
FARMINGDALE, N.Y., May 20, 2019 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that...
- May 20, 2019
Please see supporting documents for the information about a proposed settlement of a derivative action involving the company.
- May 16, 2019- Company Enters into Commercial Supply Agreement for AR101 -
BRISBANE, Calif.--(BUSINESS WIRE)--May 16, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced...
- May 16, 2019
BRISBANE, Calif.--(BUSINESS WIRE)--May 16, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced...
- May 16, 2019Hear from leading experts, including keynote speaker Gordon J. Christensen DDS, MSD, PhD, on the latest trends and innovations in dentistry
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, is proud to announce that it will host the Advancing Dentistry Symposium in San Diego, California on October 18-19, 2019. The...
- May 15, 2019— Prostate Cancer Clinical Trials Advancing; Early Clinical Observations Look Promising – — Strong Financial Results for Q2 and YTD FY 2019 — — Company to Host Investor Conference Call on Wednesday, May 15, 2019, 8 a.m. ET –
MIAMI, May 15, 2019 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU) an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and prostate cancer...
- May 15, 2019
DEER PARK, Ill., May 15, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products,...
- May 15, 2019Total revenues of approximately $9.4 million for the first quarter of 2019 compared to $6.8 million for the first quarter of 2018.
Dallas, TX, May 15, 2019 – SWK Holdings Corporation (SWKH.OB) (“SWK” or the “Company”), a life science focused specialty finance company, announced its first quarter 2019 financial results.
- May 13, 2019
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX:ASP; OTCQB:ASPCF) today reported its financial results for the three-month period ended March...
- May 13, 2019
Lake Forest, CA – May 13, 2019 – Tenex Health, Inc., a privately held U.S.-based medical technology company providing healthcare professionals with minimally invasive technologies to treat...
- May 09, 2019First Quarter U.S. Laser Revenue Increased 18% Year-Over-Year
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today reported net revenue of $10.3 million for the first quarter ended March 31, 2019, an increase of 3% compared to the first...
- May 08, 2019
MIAMI, May 08, 2019 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and prostate cancer...
- May 08, 2019Potential FDA approval of AR101 for peanut allergy expected by late January 2020; Company on target to be launch-ready in Q4 2019
BRISBANE, Calif.--(BUSINESS WIRE)--May 8, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced...
- May 08, 2019
FARMINGDALE, N.Y., May 08, 2019 (GLOBE NEWSWIRE) -- Misonix, Inc. (NASDAQ: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that...